Indication intelligence, analysis and sector perception

RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results

March 18, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 26 of 35 covered released to date    

RegMedInvestors (RMi) Research Note – finance: bluebird bio (BLUE)Secures up to $175 M Debt Financing with Hercules Capital

March 18, 2024

Blue closed up, Friday +$0.09 to $1.42 and is up +$0.03 or +2.115 pre-open Funding expected to extend BLUE’s cash runway until Q1/26 $75 million was drawn down upon closing; BLUE will be eligible to draw an additional $50 million subject to achievement of commercial milestones -

RegMed Investors (RMi) Research Note – Financing: Regenxbio (RGNX) prices 4.56 M share offering at $23.00

March 6, 2024

Size: 4.65 M shares, 1.521 (pre-funded at $22.9999)) warrents with gross of $140 M before the "usual" deductions with an option to purchase 913,050 shares again less discounts and commissions Stock dropped -$0.61 to $24.00 with a -$0.79 or -3.29% aftermarket indication Close expected by 3/11 ... Morgan Stanley, Goldman Sachs & Co. LLC, Barclays and Stifel are acting as joint book-running managers of the offering.